The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

thus preventing damage to the corneal endothelium. The stiffening effect is concentrated in the anterior 200–300 µm of the cornea due to the high absorption of UV light in this area.

A research team led by Professor Hwang Ho-sik of the Catholic University of Korea's Yeouido St. Mary's Eye Hospital has ...

Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs ...

Descemet's stripping automated endothelial keratoplasty (DSAEK) is the gold standard for the surgical treatment of corneal endothelial diseases. Following its introduction over the last decade ...

Approximately 4% of people aged 40 years and older have corneal endothelial disease/dystrophy (CED) affecting the back of the cornea, and corneal transplantation is the only treatment option for ...

Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company. It already has ...

Cloudy vision could be caused by an array of things, some benign, some not. For 65-year-old Mike Dauss, it was the latter. An abnormality was discovered during an annual eye exam in 2007. He was ...

The corneal transplant market was projected to attain US$ 444.3 million in 2023. It is likely to garner a 5.6% CAGR from 2024 ...